Cigna Group (NYSE:CI – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Saturday, Wall Street Zen reports.
Several other equities research analysts have also weighed in on CI. Wells Fargo & Company raised their target price on Cigna Group from $307.00 to $325.00 and gave the stock an “equal weight” rating in a research report on Friday, November 13th. Guggenheim lowered their price target on Cigna Group from $361.00 to $347.00 and set a “buy” rating for the company in a report on Friday, November 6th. Sanford C. Bernstein increased their price target on shares of Cigna Group from $387.00 to $390.00 and gave the company an “outperform” rating in a research note on Wednesday, November 11th. Cantor Fitzgerald reissued an “overweight” rating and set a $340.00 price objective on shares of Cigna Group in a report on Friday, November 6th. Finally, Jefferies Financial Group upped their target price on shares of Cigna Group from $288.00 to $304.00 and gave the company a “hold” rating in a report on Thursday, November 12th. Fourteen investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $337.35.
Read Our Latest Report on Cigna Group
Cigna Group Price Performance
Cigna Group (NYSE:CI – Get Free Report) last posted its earnings results on Thursday, November 5th. The health services provider reported $7.98 EPS for the quarter, beating the consensus estimate of $7.52 by $0.46. Cigna Group had a return on equity of 19.57% and a net margin of 2.09%. The firm had revenue of $73.79 billion for the quarter, compared to analyst estimates of $72.64 billion. During the same quarter in the prior year, the company posted $7.83 earnings per share. Cigna Group’s revenue for the quarter was up 5.6% compared to the same quarter last year. Equities analysts forecast that Cigna Group will post 30.70 EPS for the current fiscal year.
Insider Buying and Selling
In other news, insider Everett Neville sold 617 shares of the company’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $284.05, for a total value of $175,258.85. Following the completion of the sale, the insider directly owned 5,053 shares of the company’s stock, valued at approximately $1,435,304.65. This represents a 10.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.60% of the company’s stock.
Institutional Trading of Cigna Group
Several institutional investors and hedge funds have recently added to or reduced their stakes in CI. Defiance ETFs LLC increased its holdings in shares of Cigna Group by 13.9% in the third quarter. Defiance ETFs LLC now owns 1,170 shares of the health services provider’s stock valued at $318,000 after purchasing an additional 143 shares during the period. Kestra Advisory Services LLC raised its stake in shares of Cigna Group by 15.8% during the third quarter. Kestra Advisory Services LLC now owns 31,601 shares of the health services provider’s stock worth $8,590,000 after purchasing an additional 4,321 shares during the last quarter. Advisors Asset Management Inc. acquired a new stake in shares of Cigna Group during the third quarter worth $4,401,000. Innovator Capital Management LLC acquired a new stake in shares of Cigna Group during the third quarter worth $3,991,000. Finally, Algert Global LLC grew its position in Cigna Group by 145.9% in the 3rd quarter. Algert Global LLC now owns 29,645 shares of the health services provider’s stock valued at $8,058,000 after buying an additional 17,588 shares during the last quarter. 86.99% of the stock is owned by hedge funds and other institutional investors.
Cigna Group News Summary
These are some of the CI news items that stood out recently:
- Positive Sentiment: RBC maintained an Outperform rating and raised its price target to $346 from $337, citing Cigna’s third-quarter results and the developing 2027 outlook. RBC raises Cigna price target
- Positive Sentiment: A recent article raises the possibility that CI is undervalued following management’s UBS Healthcare Conference update, though the supplied article details do not specify the basis for that assessment. Cigna valuation discussion
- Neutral Sentiment: The Cigna Group Foundation announced $31.5 million in grants for community organizations across 10 states, supporting youth mental health, veterans, and people with complex health conditions. The announcement highlights community investment but provides no direct financial outlook update. Cigna Foundation grants
About Cigna Group
The Cigna Group is a global health services company that provides health insurance and related services through its Cigna Healthcare and Evernorth Health Services businesses. Cigna Healthcare offers medical, dental, behavioral health and other coverage and services to employers, individuals and government-program members. Evernorth provides pharmacy benefit management, specialty pharmacy, care delivery and other health services. Its offerings include prescription drug benefits and services for people with complex or chronic conditions.
Read More
- Five stocks we like better than Cigna Group
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Cigna Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna Group and related companies with MarketBeat.com's FREE daily email newsletter.
